18
Collaboration in the Life Sciences November 2011
Collaboration in the Life Sciences
November 2011
Collaboration -> Innovation -> Success
2
A Guiding Principle
3
Especially in the Pharmaceutical Industry
No single company has all the necessary skills to develop a pharmaceutical drug
No single country has all the necessary skills to develop a pharmaceutical industry
Collaboration is vital, but…
…choose your partners with care.
4
Commercial Awareness Financial Competence
Scientific Excellence
What to look for in a good partner?
True for academic groups, companies and countries…
Supportive Environment
5
How does the UK rate?
6
Commercial Awareness Financial Competence
Scientific Excellence
The UK’s Position in the Global Market
True for academic groups, companies and countries…
Supportive Environment
A Key Feature…
“Almost half of more than 90,000 research articles
published by UK researchers in 2008
had a co-author from another country”.
8
…Creating a Success Story
In Europe, the UK biotech sector is developing
– 40% of all biotechnology projects in pipeline
– 45% of new biotech drugs in late stage clinical trials
The UK is a ‘super-cluster’ with organisations concentrated around centres of excellence
– ‘Golden Triangle’ includes Cambridge, Oxford, London
400+ biotechnology companies in the UK
– Industry employs nearly 20,000 people directly
– Generating revenues of $5 billion
Possesses all round expertise in drug discovery and development, in a mature sector
Possesses all round expertise in drug discovery and development, in a mature sector
The Golden Triangle
9
A Dense Environment of Biotechnology
Key bio-cluster hubs of Cambridge, London & Oxford
Europe’s most dense region of life science companies
A highly-connected ecology of life scientists, organisations and companies.
Majority of UK’s life science research undertaken here
Location of vast majority of major Pharma’s EMEA operations
Major Pharma in Golden Triangle
Abbot LaboratoriesActelionAlmirralAmgenAstella PharmaAstraZenecaBaxter HealthcareBoston ScientificBristol Myers SquibbCambridge ConsultantsChugai Pharma EuropeDaiichi Sankyo UK LtdEisai EuropeElan PharmaEli Lilly & CoGE Healthcare
PhilipsRocheSanofi Pasteur MSDSchering PloughServierShireSiemens DiagnosticsSmiths MedicalStiefelTakeda Global R&D Centre Toyama EuropeUnited TherapeuticsUCB CelltechUnileverVertexWyeth
GenzymeGileadGlaxoSmithKlineHuntleigh HealthcareIpsenJohnson & JohnsonLundbeckMedtronicMerch Sharp & DohmeMitsubishi Pharma EuropeNapp Pharmaceutical GroupNovartisOlympusOno PharmaOSIPfizer
Future developments planned in the London - Cambridge Corridor
London Bio and finance
cluster
BioPark Cluster,Welwyn
Garden City
GSK Science Park,
Stevenage
Cambridge BioCluster
UKCMRI planned for 2016 £500M World leading research institute
GSK + Govt backed £170M science park on GSK campus for 2013
Development of Cambridge Biomedical
Campus
OxfordScience Park
Ongoing Expansion of Oxford Science Park
13
…and financial commitment
Chancellor George Osborne has said the Government will protect the £4.6 billion science budget, which will see £220
million investment in the UK Centre for Medical Research and Innovation at St Pancras, London.
NHS funding will increase from £104bn to £114bn over the next four years, the chancellor of the exchequer has
confirmed.
How can you capitalise on this Success Story?
14
15
How Technology Specialists Help Overseas Companies
Overseas
Overseas UKTI Groups
Science & Innovation Networks
In the UK
UKTI Sector & Business Groups
Investment Team
Regional Organisations
Activities
Identify and assess R&D activities
Analyse business opportunities
Promote the UK
Provide
Detailed scientific information
Access to technology and technology networks
Access to specific oganisions
Overseascompanies
Overseascompanies
UK TechnologyCapabilities
UK TechnologyCapabilities
TechnologySpecialists
TechnologySpecialists
16
Conclusions
Success in the BioPharma industry will require new models of collaboration.
The UK has a world-class life science industry, geared to international collaboration
The ‘Golden Triangle’ is home to most of the UK’s BioPharma industry, and is continuing to thrive.
UKTI can provide practical and dedicated support to companies wishing to invest in the UK.
Success in the BioPharma industry will require new models of collaboration.
The UK has a world-class life science industry, geared to international collaboration
The ‘Golden Triangle’ is home to most of the UK’s BioPharma industry, and is continuing to thrive.
UKTI can provide practical and dedicated support to companies wishing to invest in the UK.
Thank You
Contact Details
Nigel Whittle PhD MBA
Technology Specialist | Life Sciences
UK Trade & Investment1 Victoria Street
London SW1E 6SW
M: +44 (0) 7931 520 480
T: +44 (0) 1223 890 068
W: www.uktradeinvest.gov.uk
UK Trade & Investment is the Government organisation that helps UK based companies succeed in international markets. It also assists overseas companies to bring high quality investment to the UK's vibrant economy.
